Drug Profile

BA 1302

Alternative Names: BA-1302

Latest Information Update: 09 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer; Non-small cell lung cancer
New Molecular Entity Yes

Phase I Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer

28 Aug 2025 BA 1302 receives Orphan Drug status for Non-small cell lung cancer in USA, prior to August 2025
28 Aug 2025 BA 1302 receives Orphan Drug status for Pancreatic cancer in USA, prior to August 2025
19 Nov 2024 Phase-I clinical trials in Breast cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease) in China (IV) (NCT06596915) (Luye Pharma pipeline, March 2025 )

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com